Amgen in $530-Million Deal for Bispecific Immunotherapies
By
Amgen has formed a research collaboration and license agreement with Immatics Biotechnologies, a clinical-stage biopharmaceutical company based in Tuebingen, Germany and Houston, Texas, to develop T-cell engaging bispecific immunotherapies targeting…